drugset
drugset / Trial / NCT06255834

Phase 1 Study for IPG11406 in Health Volunteer

NCT06255834 ↗

Phase 1 Completed 66 enrolled Nanjing Immunophage Biotech Co., Ltd Zhejiang Hospital · collab
RandomizedSequentialDouble-blindTreatment

Summary

A phase 1, randomized, double-blind, placebo-controlled, single and multiple dose escalation study to evaluate the safety, tolerability, pharmacokinetics (PK) and food effect of orally administered IPG11406 in healthy adult participants

Timeline

Start
2024-02-24
Primary completion
2024-12-30
Completion
2024-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject IPG11406 Unknown 0.5 mg Oral
Subject IPG11406 Unknown 2 mg Oral
Subject IPG11406 Unknown 6 mg Oral
Subject IPG11406 Unknown 10 mg Oral
Subject IPG11406 Unknown 20 mg Oral
Subject IPG11406 Unknown 40 mg Oral
Subject IPG11406 Unknown 80 mg Oral

Indications

inflammatory bowel disease